Skip to main content

News

NextGen Precision Health & Ellis Fischel Cancer Center Science Seminar - January 20

 

More information and a recording of the talk is available below.

For questions about this event, please reach out to Mary Christie at mchristie@health.missouri.edu

"Engineering Nanostructured Drug and Gene Delivery Systems for Cancer Therapy"

Presented by: Hu Yang, Ph.D., Linda and Bipin Doshi Endowed Department Chair, Professor; Director, Center for Biomedical Research; Linda and Bipin Doshi Department of Chemical and Biochemical Engineering, Missouri University of Science and Technology

Date: Thursday, January 20, 2022, 4:30-5:30 p.m.

Register here

Description

With collaboration with researchers with expertise in pharmaceutics and medicine, Dr. Hu Yang’s laboratory is conducting cutting-edge research to improve therapeutic index & drug properties, achieve controlled release, enable non-invasive alternative administration and improve patient compliance; and foster translational and convergence research and education. He has been actively developing novel polymers, polymer-drug coupling chemistries, and creative approaches and models to address various challenges facing drug delivery in medication management and therapy. His ongoing projects are focused on the development and translational applications of efficient drug and gene delivery systems and formulations for cancer, ocular and cardiovascular diseases. In this talk, he will present his latest work on the development and translational application of the advanced drug and gene delivery systems for improved therapy of cancer.

Speaker Bio

Yang Headshot

Dr. Hu Yang is Department Chair and Professor in the Linda and Bipin Doshi Department of Chemical and Biochemical Engineering at Missouri University of Science and Technology (Missouri S&T). He is Linda and Bipin Doshi Endowed Chair. He also serves as Director of Center for Biomedical Research at Missouri S&T. Dr. Yang received his Ph.D. in Chemical Engineering from the University of Akron in 2004, followed by postdoctoral research in pharmaceutical sciences at the University of Wisconsin-Madison between 2004 and 2005. 2005 fall, he started his independent career with appointments with chemical and life science engineering, biomedical engineering, and pharmaceutics at Virginia Commonwealth University (VCU). He moved up in rank from Assistant Professor to Professor while he was there. He held Qimonda Endowed Chair Professorship until July 2020 when he assumed the Chair position at Missouri S&T. Dr. Yang received the prestigious Wallace Coulter Young Investigator Award in 2009 and the NSF CAREER Award in 2010. Dr. Yang is scholarly productive, and his research funding, primarily coming from the National Institutes of Health, has exceeded over $10 million. His research has resulted in more than 90 peer-reviewed articles in high-impact journals. According to a report by Stanford University, Dr. Yang is among the world’s top 2% of most-cited scientists in Biomedical Engineering discipline. Dr. Yang routinely serves on the Developmental Therapeutics (DT) Study Section for NIH.